Most pharmaceutical businesses are slow-moving by nature due to the lengthy amount of time it takes to develop a new medicine ...

AbbVie (ABBV) shares snapped eight consecutive sessions of losses as the stock closed up XYZ% at $XYZ. The North ...

In a report released today, Mohit Bansal from Wells Fargo maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target of $195.00. The company’s shares closed last Friday at $164.99 ...

AbbVie stock fell 10% after emraclidine, its drug for schizophrenia, failed during the final stages of its trials. The ...

On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...

Presbyopia is an age-related refractive condition marked by a gradual decline in near vision, typically emerging between ages ...

Continuity Biosciences, LLC, a new bioscience company dedicated to developing and commercializing cutting-edge technologies for cell ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

AbbVie’s stock price fell over 12% after emraclidine, an investigational anti-psychotic being evaluated for the treatment of ...

Meacham covers the Healthcare sector, focusing on stocks such as AbbVie, Pfizer, and Vertex Pharmaceuticals. Royalty Pharma has an analyst consensus of Strong Buy, with a price target consensus of $48 ...